相关实验视频
Updated: Jan 13, 2026

05:10
Multidisciplinary Approach to Obesity Management: A Case Report
Published on: May 30, 2025
901
用GLP-1为基础的疗法管理肥胖的营养和生活方式支持性护理建议:使用修改的Delphi方法的专家共识声明
J L Sievenpiper1,2,3, J Ard4, M Blüher5
1Departments of Nutritional Sciences and Medicine, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada.
Obesity pillars
|January 8, 2026
概括
专家一致认为,在肥胖管理中,基于葡萄糖类1的治疗方法 (GBT) 提供了营养和生活方式指导. 这些建议针对胃肠道影响和营养不足,以改善患者的治疗结果和患者的坚持.
科学领域:
- 代谢障碍和内分泌学
- 营养科学 营养科学
- 临床药理学 临床药理学
背景情况:
- 利拉格卢提德,塞马格卢提德和蒂尔泽帕提德是有效的肥胖治疗方法.
- 胃肠道副作用,营养缺乏和不良坚持可以限制长期益处.
- 临床实践缺乏直接证据,证明在基于葡萄糖类1 (GBT) 的治疗中提供营养和生活方式支持.
研究的目的:
- 为GBT患者制定基于共识的营养和生活方式策略的建议.
- 为了优化治疗经验和改善肥胖患者的健康结果,使用GBTs.
- 为管理GBT患者的医疗保健专业人员提供实际指导.
主要方法:
- 从2021年1月到2025年6月的科学出版物的范围审查.
- 一个经过修改的Delphi过程,涉及一个国际多学科专家小组.
- 为营养和生活方式干预制定临床实践建议.
主要成果:
- 开发了52个共识陈述,用于管理肥胖和与GBTs相关的并发症.
- 建议涵盖营养因素,身体组成,体力活动和胃肠道症状管理.
- 为GBT治疗的所有阶段提供了策略,包括停止治疗.
结论:
- 专家共识为GBT相关的体重管理提供了营养和生活方式干预措施的实际指导.
- 这些建议补充了针对医疗保健专业人员的现有指南.
- 需要进一步的直接证据来增强对GBT患者的最佳临床护理.
相关概念视频
Diabetes: Management and Pharmacotherapy
858
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
858
Chronic Pancreatitis II: Collaborative Care
307
The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
Assessment:
307
Glucagon-like Receptor Agonists
836
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
836
Atherosclerosis III: Management
312
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
312
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
631
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
631
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
235
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
235

